marketcaparena
Search

    DCOY

    Decoy Therapeutics Inc.

    Company overview

    Market capitalization
    $1.51M
    Employees
    11
    Latest publication
    2026-09-29
    About Decoy Therapeutics Inc.

    Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue227,629USD0USD0USD0USD0USD0USD0USD0USD
    Research Development1,304,345USD749,813USD114,429USD61,826USD116,383USD75,532USD175,344USD137,234USD
    Selling General Administrative1,326,676USD1,533,926USD403,273USD833,304USD849,182USD1,643,163USD1,313,369USD869,237USD
    General And Administrative Expenses1,326,676USD———————
    Total Operating Expenses2,631,021USD2,283,739USD517,702USD895,130USD965,565USD1,718,695USD1,488,713USD1,006,471USD
    Operating Income-2,631,021USD-2,283,739USD-9,034,562USD-895,130USD-965,565USD-1,718,695USD-1,488,713USD-1,006,471USD
    Net Income-2,373,800USD-2,224,628USD-8,977,655USD-873,467USD-957,825USD-1,709,533USD-1,463,933USD-972,121USD
    Interest Income—59,111USD56,907USD21,663USD—9,162USD24,780USD34,350USD
    Net Interest Income—59,111USD56,907USD21,663USD7,740USD9,162USD24,780USD34,350USD
    Income Before Tax—-2,224,628USD-8,977,655USD-873,467USD-957,825USD-1,709,533USD-1,463,933USD-972,121USD
    Net Income From Continuing Ops—-2,224,628USD-8,977,655USD-873,467USD-957,825USD-1,709,533USD-1,463,933USD-972,121USD
    Ebitda—-2,283,739USD-9,059,543USD-894,024USD-964,459USD-1,717,589USD-1,487,607USD-1,005,366USD
    Reconciled Depreciation—5,924USD3,833USD1,106USD1,106USD1,106USD1,106USD1,105USD
    Total Other Income Expense Net—59,111USD56,907USD21,663USD7,740USD9,162USD24,780USD34,350USD
    Cost Of Revenue——8,516,860USD1,106USD1,106USD1,106USD1,106USD1,105USD
    Gross Profit——-8,516,860USD-1,106USD-1,106USD-1,106USD-1,106USD-1,105USD
    Ebit——-9,056,225USD-895,130USD-965,565USD-1,718,695USD-1,488,713USD-1,006,471USD
    Depreciation And Amortization——-3,318USD1,106USD1,106USD1,106USD1,106USD1,105USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue0USD0USD0USD0USD1,840,216USD5,233,301USD3,465,055USD838,142USD
    Cost Of Revenue8,517,966USD4,424USD10,051USD6,677USD19,183USD——430,750USD
    Gross Profit-8,517,966USD-4,424USD-10,051USD-6,677USD1,821,033USD5,233,301USD3,465,055USD407,392USD
    Research Development368,170USD770,027USD7,173,747USD15,836,828USD8,548,520USD6,913,853USD4,018,951USD11,908,294USD
    Selling General Administrative3,727,816USD4,964,289USD5,721,197USD7,138,403USD6,104,627USD6,105,793USD7,711,181USD—
    Total Operating Expenses4,095,986USD5,734,316USD12,894,944USD31,841,140USD12,812,931USD13,019,646USD11,730,132USD22,481,615USD
    Operating Income-12,613,952USD-5,734,316USD-12,894,944USD-31,841,140USD-12,812,931USD-7,786,345USD-8,265,077USD-22,074,223USD
    Interest Income95,472USD158,539USD352,251USD218,730USD————
    Net Interest Income95,472USD158,539USD352,251USD218,730USD————
    Income Before Tax-12,518,480USD-5,575,777USD-12,542,693USD-31,607,956USD-12,768,238USD-7,352,254USD-6,936,263USD-21,922,217USD
    Net Income-12,518,480USD-5,575,777USD-12,542,693USD-31,607,956USD-12,768,238USD-7,352,254USD-6,936,263USD-21,922,217USD
    Net Income From Continuing Ops-12,518,480USD-5,575,777USD-12,542,693USD-31,607,956USD-12,768,238USD———
    Ebitda-12,613,952USD-5,729,892USD-12,884,893USD-22,968,554USD-12,793,748USD-7,592,747USD-8,135,836USD-21,846,065USD
    Reconciled Depreciation7,151USD4,424USD10,051USD6,677USD19,183USD———
    Total Other Income Expense Net95,472USD158,539USD352,251USD233,184USD44,693USD434,091USD1,328,814USD152,006USD
    Ebit—-5,734,316USD-12,894,944USD-22,975,231USD-12,812,931USD-7,610,805USD-8,263,244USD-22,074,223USD
    Depreciation And Amortization—4,424USD10,051USD6,677USD19,183USD18,058USD127,408USD228,158USD
    Unclassified Operating Expenses———8,865,909USD-1,840,216USD——10,573,321USD
    Interest Expense—————3,047USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets9,001,160USD8,423,275USD11,056,707USD6,097,032USD1,392,778USD2,339,392USD3,022,974USD3,859,164USD
    Cash And Equivalents8,289,108USD———————
    Total Current Assets8,573,308USD8,357,652USD10,985,160USD6,064,938USD1,359,578USD2,305,086USD2,987,562USD3,822,646USD
    Other Current Assets146,066USD537,044USD275,223USD1,055,258USD564,692USD506,706USD553,034USD538,617USD
    Other Non Current Assets28,775USD———————
    Total Liabilities4,680,254USD———————
    Total Current Liabilities4,680,254USD4,545,890USD5,167,738USD1,104,184USD1,481,949USD2,277,526USD1,511,279USD934,581USD
    Total Stockholder Equity4,320,906USD3,877,385USD5,888,969USD4,248,065USD-829,724USD61,866USD1,511,695USD2,924,583USD
    Total Equity Including Noncontrolling Interest4,320,906USD———————
    Property Plant Equipment Net399,077USD35,741USD40,559USD———0USD—
    Accounts Payable1,326,782USD936,030USD940,586USD1,104,184USD1,481,949USD1,470,671USD936,994USD165,801USD
    Common Stock53USD53USD53USD94USD213USD208USD144USD144USD
    Retained Earnings-99,040,526USD-96,666,726USD-94,442,098USD-85,464,443USD-84,590,976USD-83,633,151USD-81,923,618USD-80,459,685USD
    Total Liab—4,545,890USD5,167,738USD1,848,967USD2,222,502USD2,277,526USD1,511,279USD934,581USD
    Other Current Liab—384,279USD1,001,571USD744,783USD740,553USD694,625USD352,419USD439,931USD
    Capital Stock—53USD53USD94USD213USD208USD144USD144USD
    Cash—7,820,608USD10,709,937USD4,809,680USD794,886USD1,798,380USD2,434,528USD3,284,029USD
    Cash And Short Term Investments—7,820,608USD10,709,937USD4,809,680USD794,886USD1,798,380USD2,434,528USD3,284,029USD
    Current Deferred Revenue—3,225,581USD3,225,581USD—————
    Net Debt—-7,820,608USD-10,709,937USD-4,809,680USD-794,886USD-1,686,150USD-2,212,662USD-2,955,180USD
    Common Stock Shares Outstanding—531,968shares481,587shares481,587shares141,524shares110,928shares96,077shares85,457shares
    Non Current Assets Total—65,623USD71,547USD32,094USD33,200USD34,306USD35,412USD36,518USD
    Non Current Liabilities Total—0USD0USD744,783USD740,553USD0USD0USD0USD
    Non Currrent Assets Other—29,882USD30,988USD32,094USD33,200USD34,306USD35,412USD36,518USD
    Net Working Capital—3,811,762USD5,817,422USD4,215,971USD-862,924USD27,560USD1,476,283USD2,888,065USD
    Unclassified Equity—100,544,005USD100,330,961USD89,712,320USD83,760,826USD83,694,601USD83,435,025USD83,383,980USD
    Net Receivables———200,000USD————
    Short Term Debt—————112,230USD221,866USD328,849USD
    Short Long Term Debt—————112,230USD221,866USD328,849USD
    Short Long Term Debt Total—————112,230USD221,866USD328,849USD
    Accumulated Other Comprehensive Income—————0USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets11,056,707USD3,022,974USD6,586,523USD14,650,799USD40,833,868USD24,932,321USD13,894,398USD10,389,626USD
    Other Current Assets275,223USD553,034USD619,763USD803,373USD949,215USD822,050USD955,899USD411,174USD
    Total Liab5,167,738USD1,511,279USD1,299,241USD4,266,191USD2,110,883USD2,773,133USD3,313,544USD1,107,000USD
    Total Stockholder Equity5,888,969USD1,511,695USD5,287,282USD10,384,608USD38,722,985USD22,159,188USD10,580,854USD9,282,756USD
    Other Current Liab1,001,571USD352,419USD406,745USD1,407,861USD567,787USD442,349USD478,545USD4,672,995USD
    Common Stock53USD144USD393USD225USD4,524USD2,381USD451USD1,807USD
    Capital Stock53USD144USD49USD225USD181USD———
    Retained Earnings-94,442,098USD-81,923,618USD-76,347,841USD-63,805,148USD-32,197,192USD-19,428,954USD-12,076,700USD-132,961,275USD
    Cash10,709,937USD2,434,528USD5,899,910USD12,106,435USD29,214,380USD11,118,614USD3,738,900USD9,829,624USD
    Cash And Short Term Investments10,709,937USD2,434,528USD5,899,910USD12,106,435USD29,214,380USD11,118,614USD3,738,900USD9,829,624USD
    Total Current Assets10,985,160USD2,987,562USD6,519,673USD14,520,298USD30,163,595USD15,796,660USD4,694,799USD10,315,166USD
    Total Current Liabilities5,167,738USD1,511,279USD1,299,241USD4,266,191USD2,110,883USD2,773,133USD3,313,544USD5,015,525USD
    Current Deferred Revenue3,225,581USD—————541,701USD4,006,755USD
    Net Debt-10,709,937USD-2,212,662USD-5,610,267USD-12,106,435USD-29,214,380USD-10,641,586USD-3,236,568USD-9,829,624USD
    Accounts Payable940,586USD936,994USD602,853USD2,858,330USD1,543,096USD1,853,756USD1,790,966USD342,530USD
    Property Plant Equipment Net40,559USD0USD——7,880USD22,639USD25,016USD74,000USD
    Common Stock Shares Outstanding481,587shares64,147shares27,205shares17,704shares13,788shares5,192shares1,089shares21shares
    Non Current Assets Total71,547USD35,412USD66,850USD130,501USD10,670,273USD9,135,661USD9,199,599USD74,460USD
    Non Current Liabilities Total0USD0USD0USD0USD0USD———
    Non Currrent Assets Other30,988USD35,412USD66,850USD130,501USD185,994USD247,113USD308,674USD460USD
    Net Working Capital5,817,422USD1,476,283USD5,220,432USD10,254,107USD28,052,712USD———
    Unclassified Equity100,330,961USD83,435,025USD81,634,681USD74,189,306USD70,915,472USD41,585,761USD22,657,103USD142,242,224USD
    Short Term Debt—221,866USD289,643USD——477,028USD502,332USD—
    Short Long Term Debt—221,866USD289,643USD—————
    Short Long Term Debt Total—221,866USD289,643USD——477,028USD502,332USD—
    Good Will———0USD8,865,909USD8,865,909USD8,865,909USD—
    Net Receivables———1,610,490USD—3,855,996USD—9,939USD
    Unclassified Non Current Assets————1,610,490USD———
    Inventory———————186,920USD
    Unclassified Current Liabilities———————-4,006,755USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation19,556USD
    Stock Based Compensation419,221USD
    Change To Liabilities-881,221USD
    Change In Working Capital-735,646USD
    Operating Cash Flow-5,541,348USD
    Investing Cash Flow-42,424USD
    Financing Cash Flow3,162,943USD
    Change In Cash-2,420,829USD
    End Cash Flow8,289,108USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-2,224,628USD-8,977,655USD-873,467USD-957,825USD-1,709,533USD-1,463,933USD-972,121USD-1,424,433USD
    Depreciation5,924USD3,833USD1,106USD1,106USD1,106USD1,106USD1,105USD1,106USD
    Stock Based Compensation213,044USD139,523USD22,846USD23,155USD33,534USD51,045USD60,009USD85,168USD
    Other Non Cash Items-883,669USD6,640,186USD22,846USD23,155USD33,534USD51,045USD60,009USD85,168USD
    Change In Working Capital-883,669USD1,057,625USD-797,174USD71,267USD493,179USD669,264USD-445,665USD265,967USD
    Total Cash From Operating Activities-2,889,329USD-1,136,488USD-1,646,689USD-862,297USD-1,181,714USD-742,518USD-1,356,672USD-1,072,192USD
    Capital Expenditures0USD-4USD0USD-3USD-4USD0USD0USD0USD
    Free Cash Flow-2,889,329USD-1,136,484USD-1,646,689USD-862,297USD-1,181,710USD-742,518USD-1,356,672USD-1,072,190USD
    Net Borrowings0USD0USD0USD-112,230USD-109,636USD-106,983USD-69,879USD—
    Total Cash From Financing Activities0USD6,072,010USD5,861,483USD-141,197USD545,566USD-106,983USD1,367,878USD-28,190USD
    Issuance Of Capital Stock0USD6,072,010USD5,861,483USD-28,967USD655,202USD0USD1,437,757USD—
    Change In Cash-2,889,329USD5,900,257USD4,014,794USD-1,003,494USD-636,148USD-849,501USD11,206USD-1,100,382USD
    Begin Period Cash Flow10,709,937USD4,809,680USD794,886USD1,798,380USD2,434,528USD3,284,029USD3,272,823USD4,373,205USD
    End Period Cash Flow7,820,608USD10,709,937USD4,809,680USD794,886USD1,798,380USD2,434,528USD3,284,029USD3,272,823USD
    Total Cashflows From Investing Activities—964,735USD-200,000USD—————
    Other Cashflows From Investing Activities—-377,000USD-200,000USD—————
    Other Cashflows From Financing Activities—6,072,010USD5,861,483USD—————
    Unclassified Investing Cash Flow—1,341,739USD——————
    Unclassified Financing Cash Flow—-6,072,010USD-5,861,483USD—————
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-12,518,480USD-5,575,777USD-12,542,693USD-31,607,956USD-12,768,238USD-7,352,254USD-6,936,263USD-21,922,217USD
    Depreciation7,151USD4,424USD10,051USD6,677USD19,183USD18,058USD127,408USD228,158USD
    Stock Based Compensation219,058USD273,730USD524,838USD796,803USD559,044USD319,391USD751,618USD1,939,611USD
    Other Non Cash Items7,465,083USD273,730USD130,000USD10,839,355USD-44,693USD-258,551USD-1,311,333USD31,847USD
    Change In Working Capital-1,046,343USD772,286USD-968,333USD2,369,800USD2,034,507USD-3,038,007USD-4,211,526USD-3,876,059USD
    Total Cash From Operating Activities-4,827,188USD-4,525,337USD-12,846,137USD-17,595,321USD-10,200,197USD-10,311,363USD-11,580,096USD-23,598,660USD
    Capital Expenditures-577,000USD-3USD-3USD-1,500,000USD-3USD-2,600USD-4USD0USD
    Free Cash Flow-4,827,188USD-4,525,337USD-12,846,137USD-19,095,321USD-10,200,197USD-10,313,963USD-11,580,096USD-23,598,660USD
    Total Cashflows From Investing Activities764,735USD——-1,500,000USD—-2,600USD5,607,908USD14,124,238USD
    Net Borrowings-221,866USD-466,505USD-280,917USD0USD-477,028USD———
    Total Cash From Financing Activities12,337,862USD1,059,955USD6,639,612USD1,987,376USD28,295,963USD17,693,677USD3,579,307USD118,010USD
    Issuance Of Capital Stock12,559,728USD1,526,460USD6,920,529USD1,987,376USD27,287,638USD———
    Change In Cash8,275,409USD-3,465,382USD-6,206,525USD-17,107,945USD18,095,766USD7,379,714USD-2,392,881USD-9,356,412USD
    Begin Period Cash Flow2,434,528USD5,899,910USD12,106,435USD29,214,380USD11,118,614USD3,738,900USD6,131,781USD19,312,631USD
    End Period Cash Flow10,709,937USD2,434,528USD5,899,910USD12,106,435USD29,214,380USD11,118,614USD3,738,900USD9,956,219USD
    Other Cashflows From Investing Activities-577,000USD—3USD-1,500,000USD——204,274USD4,805USD
    Other Cashflows From Financing Activities12,337,862USD———1,485,353USD3,869,168USD—118,010USD
    Unclassified Operating Cash Flow1,046,343USD———————
    Unclassified Investing Cash Flow1,918,735USD——1,500,000USD——5,403,638USD14,119,433USD
    Unclassified Financing Cash Flow-12,337,862USD————13,824,509USD3,712,901USD—
    Change To Account Receivables——1,480,490USD—2,245,506USD-3,855,996USD690USD7,206USD
    Change To Inventory——————1,169USD227,979USD
    Dividends Paid——————-133,594USD—
    Sale Purchase Of Stock———————-615,014USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2019Quarterly · 2019-06-30ProductProduct163,071USD0001615219-19-000024
    Q2 2019Quarterly · 2019-06-30ProductProduct And Service Other1,634USD0001615219-19-000024
    Q2 2019Quarterly · 2019-06-30SegmentConsumer Operations164,705USD0001615219-19-000024
    Q2 2019Quarterly · 2019-06-30SegmentDrug Development0USD0001615219-19-000024
    Q1 2019Quarterly · 2019-03-31ProductProduct104,220USD0001615219-19-000020
    Q1 2019Quarterly · 2019-03-31ProductProduct And Service Other757USD0001615219-19-000020
    Q1 2019Quarterly · 2019-03-31SegmentConsumer Operations104,977USD0001615219-19-000020
    Q1 2019Quarterly · 2019-03-31SegmentDrug Development0USD0001615219-19-000020
    Q4 2018Quarterly · 2018-12-31ProductProduct161,560USD0001615219-19-000008
    Q4 2018Quarterly · 2018-12-31ProductProduct And Service Other1,507USD0001615219-19-000008
    Q4 2018Quarterly · 2018-12-31SegmentConsumer Operations163,067USDLegacy provider
    Q4 2018Quarterly · 2018-12-31SegmentDrug Development0USDLegacy provider
    FY 2018Yearly · 2018-12-31ProductProduct826,515USD0001615219-19-000008
    FY 2018Yearly · 2018-12-31ProductProduct And Service Other11,627USD0001615219-19-000008
    FY 2018Yearly · 2018-12-31SegmentConsumer Operations838,142USD0001615219-19-000008
    FY 2018Yearly · 2018-12-31SegmentDrug Development0USD0001615219-19-000008
    Q3 2018Quarterly · 2018-09-30ProductProduct247,284USD0001615219-19-000008
    Q3 2018Quarterly · 2018-09-30ProductProduct And Service Other3,707USD0001615219-19-000008
    Q3 2018Quarterly · 2018-09-30SegmentConsumer Operations250,991USD0001615219-18-000061
    Q3 2018Quarterly · 2018-09-30SegmentDrug Development0USD0001615219-18-000061
    Q2 2018Quarterly · 2018-06-30ProductProduct241,416USD0001615219-19-000024
    Q2 2018Quarterly · 2018-06-30ProductProduct And Service Other4,086USD0001615219-19-000024
    Q2 2018Quarterly · 2018-06-30SegmentConsumer Operations245,502USD0001615219-19-000024
    Q2 2018Quarterly · 2018-06-30SegmentDrug Development0USD0001615219-19-000024
    Q1 2018Quarterly · 2018-03-31ProductProduct176,255USD0001615219-19-000020
    Q1 2018Quarterly · 2018-03-31ProductProduct And Service Other2,327USD0001615219-19-000020
    Q1 2018Quarterly · 2018-03-31SegmentConsumer Operations178,582USD0001615219-19-000020
    Q1 2018Quarterly · 2018-03-31SegmentDrug Development0USD0001615219-19-000020
    Q4 2017Quarterly · 2017-12-31ProductProduct282,752USD0001615219-19-000008
    Q4 2017Quarterly · 2017-12-31ProductProduct And Service Other76USD0001615219-19-000008
    Q4 2017Quarterly · 2017-12-31SegmentConsumer Operations282,828USDLegacy provider
    Q4 2017Quarterly · 2017-12-31SegmentDrug Development0USDLegacy provider
    FY 2017Yearly · 2017-12-31ProductProduct1,260,973USD0001615219-19-000008
    FY 2017Yearly · 2017-12-31ProductProduct And Service Other13,526USD0001615219-19-000008
    FY 2017Yearly · 2017-12-31SegmentConsumer Operations1,274,499USD0001615219-19-000008
    FY 2017Yearly · 2017-12-31SegmentDrug Development0USD0001615219-19-000008
    Q3 2017Quarterly · 2017-09-30ProductProduct407,241USD0001615219-19-000008
    Q3 2017Quarterly · 2017-09-30ProductProduct And Service Other6,360USD0001615219-19-000008
    Q3 2017Quarterly · 2017-09-30SegmentConsumer Operations413,601USD0001615219-18-000061
    Q3 2017Quarterly · 2017-09-30SegmentDrug Development0USD0001615219-18-000061
    FY 2016Yearly · 2016-12-31ProductProduct989,918USD0001615219-19-000008
    FY 2016Yearly · 2016-12-31ProductProduct And Service Other20,745USD0001615219-19-000008
    FY 2016Yearly · 2016-12-31SegmentConsumer Operations1,010,663USD0001615219-19-000008
    FY 2016Yearly · 2016-12-31SegmentDrug Development0USD0001615219-19-000008

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.